

The Diagnostic and Predictive Value of Different Biomarkers in Pancreatic Juice and blood in Patients with Pancreatic Cancer

Gepubliceerd: 30-10-2018 Laatste bijgewerkt: 19-03-2025

We hypothesize to find an association between these ct-DNA levels in pancreatic juice and blood and (progression-free) survival.

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON25284

Bron

NTR

Verkorte titel

KRAS^{Panc}

Aandoening

Pancreatic cancer

Ondersteuning

Primaire sponsor: Erasmus University Medical Center

Overige ondersteuning: investigator initiated.

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Toelichting onderzoek

Achtergrond van het onderzoek

The incidence of pancreatic cancer (PC) in the Netherlands is low, yet the prognosis is dismal. In 2030, PC is even expected to be the number one cause of cancer related death, worldwide. At present, PC diagnosis is based on imaging, yet the development of biomarkers is needed, not only to enable timely detection, but also to allow personalised care and early prediction of treatment response. Individual biomarkers seem to have a limited predictive value. A broad approach is needed, investigating different molecular markers in different biomaterials (serum and pancreatic juice) to develop a combination of tests that will improve PC survival. We expect to detect cellular and extra-cellular components of the tumour in pancreatic juice and serum (ct-DNA, cytokines, fibrotic mediators), serving as promising targets for biomarker detection.

Doel van het onderzoek

We hypothesize to find an association between these ct-DNA levels in pancreatic juice and blood and (progression-free) survival.

Onderzoeksopzet

Pancreatic juice and serum collections will be performed during EUS. Further disease and survival characteristics will be collected up to 2 year after inclusion.

Onderzoeksproduct en/of interventie

No interventions

Contactpersonen

Publiek

Wetenschappelijk

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

All patients with (suspected) pancreatic cancer that undergo an EUS either as part of a diagnostic process or for fiducial placement prior to treatment.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

A potential subject that is younger than 18 years old will be excluded from participation in this study.

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	30-10-2018
Aantal proefpersonen:	200
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum: 30-10-2018
Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 54838
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL7383
NTR-old	NTR7591
CCMO	NL64724.078.18
OMON	NL-OMON54838

Resultaten